Cloning, expression and immunity of pilA gene and ompC gene from avian pathogenic Escherichia coli.
- Author:
Shan YU
1
;
Qian ZHANG
;
Xiaoxi SHUI
;
Zhouliang YU
;
Baohua ZHAO
Author Information
1. College of Life Sciences, Hebei Normal University, Shijiazhuang 050016, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cloning, Molecular;
Escherichia coli;
genetics;
immunology;
metabolism;
Escherichia coli Proteins;
genetics;
immunology;
metabolism;
Escherichia coli Vaccines;
immunology;
Fimbriae Proteins;
genetics;
immunology;
metabolism;
Gene Expression Regulation, Bacterial;
Genes, Bacterial;
Mice;
Porins;
genetics;
immunology;
metabolism;
Recombinant Fusion Proteins;
genetics;
immunology;
metabolism
- From:
Chinese Journal of Biotechnology
2008;24(9):1561-1567
- CountryChina
- Language:Chinese
-
Abstract:
In order to amplify pilA gene and ompC gene of avian pathogenic Escherichia coli (APEC) strain, two pairs of primers were designed according to the GenBank sequences, and a 549 bp pilA gene and a 1104 bp ompC gene were obtained by PCR separately. Sequence analysis indicated that the homology of the nucleotide sequence of AEPC strain to those other reference strains was 98.18% of the pilA gene and 97.28% of the ompC gene. Two expression plasmids pETpilA and pETompC were constructed by inserting pilA gene and ompC gene into the prokaryotic expression vector pET-28a. The two plasmids were transformated into E. coli BL21 separately and two recombinant strains BL21 (pETpilA) and BL21 (pETompC) were obtained. The type 1 fimbraie and the out membrane protein were highly expressed when the recombinant strain BL21 (pETpilA) and BL21 (pETompC) were induced by IPTG Two specific proteins were detected by SDS-PAGE and immunogenicity of the expressed protein was confirmed by Western blotting and ELISA. The expressed fimbraie and OmpC were transformed into vaccine. The protective immune response was proved after the mice were immunized with the two vaccines. The results showed that the recombinant strain BL21 (pETpilA) and BL21 (pETompC) could be as candidate vaccine to provide protective immune response against AEPC infection.
